Lakewood-Amedex Biotherapeutics Inc.
LABT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002079272
No open-market purchases or sales by Lakewood-Amedex Biotherapeutics Inc. insiders were filed in the last 90 days; 6 institutions reported holding it in 13F filings for Q2 2026, worth $306.5K in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +6 vs. previous quarter
- 6
- 13F valueReported value at the end of Q2 2026
- $306.5K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding LABT, Q2 2026
No superinvestor reported holding LABT at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Lakewood-Amedex Biotherapeutics Inc. insiders from Form 4, newest first.
No open-market purchases or sales by Lakewood-Amedex Biotherapeutics Inc. insiders are on file.
Top 10 13F holders, Q2 2026
The largest institutional positions in Lakewood-Amedex Biotherapeutics Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Marex Group plc | 48,167 | $151.2K | 0.00% | +48,167 | New |
| HRT Financial LP | 44,782 | $140.0K | 0.00% | +44,782 | New |
| UBS Group AG | 4,098 | $12.9K | 0.00% | +4,098 | New |
| Tower Research Capital LLC (TRC) | 624 | $1.96K | 0.00% | +624 | New |
| Advisor Group Holdings, Inc. | 138 | $433 | 0.00% | +138 | New |
| Ronald Blue Trust, Inc. | 11 | $35 | 0.00% | +11 | New |